Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

Non-alcoholic Fatty Liver Disease (NAFLD) and its progressive form or NASH with fibrosis, are rapidly increasing in conjunction with the growing rates of obesity and type II diabetes. Novel technologies such as epigenome-wide association studies (EWAS) may provide opportunities to get valuable insight into not only the mechanisms of disease, but to also discover potential biomarker targets with clinical relevance to disease stage.